

Express Mail No. EV913329554US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Michael A. Zeligs

Confirmation No.: 2485

Serial No.: 10/765,792

Art Unit: 1618

Filed: January 26, 2004

Examiner: Ebrahim, Nabila G

For: Phytochemicals for the
Treatment of Endometriosis

Attorney Docket No: 9439-016-999

**STATEMENT OF THE SUBSTANCE
OF THE INTERVIEW UNDER § 37 C.F.R. 1.133**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. § 1.133(b) and MPEP 713.04, Attorneys for Applicant submit this Statement of the Substance of the Interview in connection with the interview on October 3, 2007 between Examiner Nabila G. Ebrahim and Attorney for Applicant, Thomas E. Friebe, in connection with the above-identified application.

During the interview on October 3, 2007, Examiner Ebrahim and Mr. Friebe discussed the Applicant's September 26, 2007 response to the non-final Office Action mailed May 10, 2007 including the declaration of the inventor Dr. Michael Zeligs which presented evidence that the claimed invention had been reduced to practice prior to the publication date of the Liang reference. Examiner Ebrahim and Mr. Friebe also discussed support for the new claims suggested by the Examiner.


Accordingly, Attorneys for Applicant respectfully request entry of the foregoing remarks into the file history of the above-identified application and that the Patent Office issue a second substantive Office Action.

It is believed that no fee is due in connection with the filing of this Statement. However, should the Patent Office determine that a fee is due, please charge the required fee to Jones Day Deposit Account No. 50-3013. A copy of this sheet is enclosed.

Date:

11-13-07

Respectfully submitted,



Thomas E. Friebe

29,258

(Reg. No.)

Jones Day

222 East 41st Street

New York, New York 10017-6701

(212) 326-3811